Enhancement of systemic and lung-localized CD4+ T-cell immune responses by truncation of NS1 protein of a seasonal live influenza vaccine strain
Journal of microbiology, epidemiology and immunobiology · 18.11.2024 · 101 (5) · 619-627
DOI: 10.36233/0372-9311-582 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of microbiology, epidemiology and immunobiology, online erschienen am 18.11.2024. Verfasst von Polina I. Prokopenko und 11 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
There is a large variety of licensed influenza vaccines worldwide, but their common limitation is rather narrow specificity and inability to protect against antigenic-drift variants of influenza virus. Therefore, optimization of immunogenic and cross-protective properties of licensed influenza vaccines is an urgent priority of public health agenda. One such approach is to modulate the immunogenic properties of live attenuated influenza vaccine (LAIV) by truncating the open reading frame of influenza virus non-structural protein 1 (NS1). The main objective of this study is to evaluate the immunogenic properties of the H1N1 seasonal LAIV strain by truncation of the NS1 protein to 126 amino acides. Materials and methods. Using reverse genetics technique, two H1N1 LAIV strains with full-length and truncated NS1 protein with three consecutive stop codons added after the 126th amino acid residue were obtained.C57BL/6J mice were immunized intranasally with the vaccine candidates, twice at a three-week interval. Seven days after the second immunization, cells were isolated from spleen and lung tissues and stimulated with whole wild-type H1N1 influenza virus. Levels of systemic and tissue-resident cytokine-producing CD4+ and CD8+ memory T cells were assessed by intracellular cytokine staining assay with flow cytometry. Replication of engineered vaccine strains in in vitro and in vivo systems was also evaluated.
Results
Truncation of NS1 protein of the LAIV strain significantly increased the levels of virus-specific CD4+ effector memory T cells in spleens and the levels of CD4+ tissue-resident memory T cells in lungs of mice after two-dose immunization, indicating a higher potential for protection against influenza infection of the LAIV NS126 vaccine strain compared to the classical variant of LAIV. Importantly, the LAIV NS126 strain also had a more pronounced attenuated phenotype in mice than its classical counterpart.
Zitieren
APA
Prokopenko, P. I., Stepanova, E. A., Matyushenko, V. A., Rak, A. Y., Chistyakova, A. K., Kostromitina, A. D., Kotomina, T. S., Kudryavtsev, I. V., Rubinstein, A. A., Komlev, A. S., Rudenko, L. G., & Isakova-Sivak, I. N. (2024). Enhancement of systemic and lung-localized CD4+ T-cell immune responses by truncation of NS1 protein of a seasonal live influenza vaccine strain. Journal of microbiology, epidemiology and immunobiology, 101(5), 619-627. https://doi.org/10.36233/0372-9311-582
Vancouver
Prokopenko PI, Stepanova EA, Matyushenko VA, Rak AY, Chistyakova AK, Kostromitina AD, et al. Enhancement of systemic and lung-localized CD4+ T-cell immune responses by truncation of NS1 protein of a seasonal live influenza vaccine strain. Journal of microbiology, epidemiology and immunobiology. 2024;101(5):619-627. doi:10.36233/0372-9311-582
BibTeX
@article{Prokopenko2024,
author = {Prokopenko, Polina I. and Stepanova, Ekaterina A. and Matyushenko, Victoria A. and Rak, Alexandra Ya. and Chistyakova, Anna K. and Kostromitina, Arina D. and Kotomina, Tatyana S. and Kudryavtsev, Igor V. and Rubinstein, Artem A. and Komlev, Alexey S. and Rudenko, Larisa G. and Isakova-Sivak, Irina N.},
title = {Enhancement of systemic and lung-localized CD4+ T-cell immune responses by truncation of NS1 protein of a seasonal live influenza vaccine strain},
journal = {Journal of microbiology, epidemiology and immunobiology},
year = {2024},
volume = {101},
number = {5},
pages = {619--627},
doi = {10.36233/0372-9311-582}
}
EUVIMED